Romidepsin News and Research

RSS
Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

Moffitt study may lead to potential treatment options for cutaneous T cell lymphoma

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

FDA awards six clinical trial research grants to enhance development of therapies for rare diseases

Study: Pleotropic drugs can have both favorable and unfavorable effects on cell growth, survival

Study: Pleotropic drugs can have both favorable and unfavorable effects on cell growth, survival

Study: Understanding second-degree burns is key to treating these complications

Study: Understanding second-degree burns is key to treating these complications

Targeting HDAC2 reduces MDM2 expression and has anti-tumor effects in dedifferentiated liposarcoma

Targeting HDAC2 reduces MDM2 expression and has anti-tumor effects in dedifferentiated liposarcoma

New active pharmaceutical ingredient may help against severe forms of testicular cancer

New active pharmaceutical ingredient may help against severe forms of testicular cancer

HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

HDAC inhibitors could improve activity of immunotherapeutic antibodies in lung cancer patients

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Pilot study shows that anti-cancer drug can activate hidden HIV

Pilot study shows that anti-cancer drug can activate hidden HIV

Phase II study reveals potential biomarker for HIV vaccine

Phase II study reveals potential biomarker for HIV vaccine

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

Researchers discover new approach to treat two lethal metastatic cancers

Researchers discover new approach to treat two lethal metastatic cancers

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Updated Phase 1 study results of FOLOTYN in patients with refractory CTCL presented at ASH 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint